The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms
- PMID: 9366322
- DOI: 10.1016/s0022-5347(01)68167-9
The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms
Abstract
Purpose: Tests to detect recurrent bladder neoplasms are limited and none is consistently accurate. Recent studies suggest that the bladder tumor antigen (BTA) test, an agglutination reaction for basement membrane complexes, is superior to voided urine cytology in clinical practice. We compared BTA and voided urine cytology to bladder washings and cystoscopy, emphasizing diagnostic yield among patients with causes of basement membrane complexes other than bladder cancer.
Materials and methods: Random voided urine specimens from 67 patients with a history of bladder neoplasms were collected before cystoscopy and bladder washing. Urine also was obtained from 34 patients with inflammatory bladder conditions including 5 with a history of prostate cancer. Each urine was tested for BTA according to a commercial kit. Positive results were indicated by yellow on a test pad. Blinded to all other results, each urine and each bladder washing were examined microscopically, and a positive test had malignant/suspicious cells. Bladder biopsies were performed when endoscopic lesions were seen. Specimens were grouped into 4 categories: group 1--biopsy proved bladder neoplasm, group 2--history of bladder cancer but not biopsy proved, group 3--history of prostate cancer and group 4--no history of urological cancer.
Results: Voided urine cytology was positive in 54% of specimens from patients with biopsy proved bladder neoplasms compared to 29% for BTA. Relative yield for voided urine cytology versus BTA was not changed if all group 2 cases having a positive bladder washing and positive cystoscopy were assumed to have bladder cancer, nor was relative yield altered by subsequent short-term followup. Of voided urine specimens 14% from group 1 patients and 41% from group 2 patients had scant cells. Overall diagnostic yield was superior for bladder washing. False-positive BTA occurred in 7 of 34 patients with no history of urological or prostate cancer. There were no false-positive voided urine cytology interpretations in these groups.
Conclusions: BTA is not superior to voided urine cytology in detecting bladder neoplasms and may be limited by false-positive reactions in patients with other causes of basement membrane complexes in urine. Voided urine samples may be limited by high frequency of hypocellularity. Of 34 patients with a hypocellular urine specimen 4 had biopsy proved bladder cancer. Bladder washing yields best results but requires instrumentation. No test, including cystoscopy, is accurate always.
Comment in
-
Data interpretation and integration of new tests into clinical practice.J Urol. 1997 Dec;158(6):2107-8. doi: 10.1016/s0022-5347(01)68168-0. J Urol. 1997. PMID: 9366323 No abstract available.
Similar articles
-
Human complement factor H related protein test for monitoring bladder cancer.J Urol. 2001 Feb;165(2):374-7. doi: 10.1097/00005392-200102000-00005. J Urol. 2001. PMID: 11176376 Clinical Trial.
-
Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.Urology. 1997 May;49(5):786-9. doi: 10.1016/S0090-4295(97)00081-2. Urology. 1997. PMID: 9145993 Clinical Trial.
-
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.Eur Urol. 1999 Jan;35(1):52-6. doi: 10.1159/000019819. Eur Urol. 1999. PMID: 9933795 Clinical Trial.
-
Current status of urinary cytology in the evaluation of bladder neoplasms.Hum Pathol. 1990 Sep;21(9):886-96. doi: 10.1016/0046-8177(90)90171-z. Hum Pathol. 1990. PMID: 2203672 Review.
-
Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.Urology. 1995 Aug;46(2):173-7. doi: 10.1016/s0090-4295(99)80189-7. Urology. 1995. PMID: 7624989 Review.
Cited by
-
Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.Int Urol Nephrol. 1999;31(2):189-96. doi: 10.1023/a:1007124724817. Int Urol Nephrol. 1999. PMID: 10481963
-
[Exfoliative urine cytology in the treatment of bladder cancer].Urologe A. 2011 Mar;50(3):292-6. doi: 10.1007/s00120-010-2410-9. Urologe A. 2011. PMID: 21365347 German.
-
CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research.Front Oncol. 2024 Sep 10;14:1445526. doi: 10.3389/fonc.2024.1445526. eCollection 2024. Front Oncol. 2024. PMID: 39319055 Free PMC article.
-
Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.Am J Clin Pathol. 2021 Oct 13;156(5):926-933. doi: 10.1093/ajcp/aqab050. Am J Clin Pathol. 2021. PMID: 34086841 Free PMC article.
-
Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(4):221-7. doi: 10.1007/BF01901608. Int Urogynecol J Pelvic Floor Dysfunct. 1998. PMID: 9795828 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical